OR WAIT null SECS
June 02, 2012
Extensive physicochemical characterization of the innovator product and the proposed biosimilar provides the foundation for demonstrating biosimilarity.
June 01, 2012
A number of factors need to be considered when evaluating preclinical dose-formulation stability. The authors discuss formulation, storage and dosing conditions.
May 02, 2012
Targeted polymeric nanoparticles are an important vehicle for controlling and targeting dosing of chemotherapeutic agents.
Industry experts working with extended-release injectables discuss challenges and solutions to formulating and manufacturing these complex products.
The author discusses potential opportunities to improve the patient experience through formulation and delivery device technologies.
May 01, 2012
If a product does not have its own antimicrobial properties, then a preservative must be used to ensure microbiological safety.
April 02, 2012
In Part III of a three-part article, the authors examine various degradation routes of APIs, impurities arising from interactions in formulations, metabolite impurities, various analytical methods to measure impuritie, and ways to control impurities.
Critical issues that should be considered when scaling up a hot-melt extrusion process.
How to use geographic diversification and legacy technology transfers to avoid product shortages.
Excipient manufacturers expand production capacity and partner to broaden their offerings.